DAMORA THERAPEUTICS, INC. Cash Equivalents, at Carrying Value
DAMORA THERAPEUTICS, INC. (DMRA) had Cash Equivalents, at Carrying Value of $19.70 million as of 2024-09-30, per its 10-Q filed 2024-11-01.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2024-11-01
- 2024-09-30: Cash Equivalents, at Carrying Value $19.70M.
- 2024-06-30: Cash Equivalents, at Carrying Value $22.90M.
- 2019-12-31: Cash Equivalents, at Carrying Value $0.00.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2024-09-30 | $19.70M 10-Q · filed 2024-11-01 |
| 2024-06-30 | $22.90M 10-Q · filed 2024-08-12 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |